Local environment
Our research unit is based on close collaborations with several structures and biotechs. hosted on our premises.
Hospital environment
Hôpital Bicêtre
The center for familial amyloid neuropathies and other rare peripheral neuropathies (NNERF) provides comprehensive management of these diseases, by improving access to diagnosis, offering the best treatment and ensuring patient information and training. and his family.
Research infrastructure
NeurATRIS is a national research infrastructure to accelerate the translation of discoveries in basic research into medical innovations for the treatment of neurodegenerative and neurodevelopmental diseases. Its objective is to offer a continuum of translational expertises ranging from in vitro cellular models to phase II clinical trials on patients suffering from major brain diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Multiple Sclerosis (MS) or certain brain development disorders. Organized as a one-stop network, NeurATRIS is designed to co-ordinate research activities and technological development serving the scientific and industrial communities.
Research institute
The Baulieu Institute is evaluating the modulating and potentially protective role of the FKBP52 protein in senile dementias (TAUopathies, including Alzheimer’s disease). He also assesses the synaptic damage associated with Alzheimer’s disease and various therapeutic approaches to correct it.
Biotechnology companies
CryoCapCell is developing an innovative technology to perform multimodal microscopic imaging analyses, with a particular focus on CLEM correlative microscopy, which combines light and electron microscopy.
Most pathologies of the nervous system do not currently have effective treatments. MAAsiRNA is dedicated to the development of targeted therapy based on interfering RNA (siRNA). After more than a decade of research in our laboratory, we have developed an siRNA-based treatment for the world’s most common inherited peripheral neuropathy, Charcot-Marie-Tooth disease type 1A (CMT1A). CMT1A affects one in 5,000 people, totaling 1.5 million people worldwide. Our current goal is to progress toward a therapy that can be administered to patients.
Mapreg stimulates microtubule dynamics to rescue neuronal function in the context of traumatic brain injury, psychiatric diseases, neurodegenerative diseases, and strokes.